Genentech And Biogen Idec Announce Top-Line Results From A Phase II/III Clinical Trial Of Rituxan In Primary-Progressive Multiple Sclerosis
May 15th 2008Drug InformationMultiple Sclerosis
Genentech, Inc. (NYSE: DNA) and Biogen Idec, Inc. (Nasdaq: BIIB) announced that a Phase II/III study of RituxanŽ (rituximab) for primary-progressive multiple sclerosis (PPMS) did not meet its primary endpoint as measured by the time to confirmed disease progression during the 96-week treatment period. Genentech and Biogen Idec will continue to analyze the study results and will submit the data for presentation at an upcoming medical meeting.
More: continued here
No Comments »
Leave a Reply
You must be logged in to post a comment.
